Rosetta to Delay Certain miRNA Diagnostics as It Markets Certain Others Itself

The company is aiming to market two of its miRNA diagnostics in the US on its own, and will delay the launch of certain other next-generation tests as a result.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.